Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Colorectal Cancer Reports
Published in: Current Colorectal Cancer Reports 1/2014

01-03-2014 | Prevention and Early Detection (N Arber, Section Editor)

Curcumin Alone and in Combination for Prevention of Colorectal Cancer

Authors: Nataly Shemesh, Nadir Arber

Published in: Current Colorectal Cancer Reports | Issue 1/2014

Login to get access

Abstract

Colorectal cancer (CRC) is a major health concern. It is the third most common type of cancer and cause of death by cancer. Chemoprevention is a promising approach for reducing morbidity and mortality from CRC. The search for a chemoprevention agent with mild side effects has led to particular interest in curcumin. In-vitro and in-vivo studies indicate that curcumin can interfere with multiple cell signaling pathways involved in carcinogenesis, including inhibition of cell cycle progression, induction of apoptosis, slowing of proliferation, and reduction of angiogenesis, invasion, and metastasis formation. Curcumin is also a very potent anti-inflammatory agent and anti-oxidative agent. Curcumin has no adverse effects on normal cells, making it a very promising chemopreventive agent.
Literature
1.
2.
Arber N. Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point. Cancer Epidemiol Biomarkers Prev. 2008;17:1852–7.PubMedCrossRef
3.
4.
Baron JA, Sandler RS, Bresalier RS, et al. APPROVe Trial Investigators. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology. 2006;131:1674–82.PubMedCrossRef
5.
Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355:873–84.PubMedCrossRef
6.
Arber N, Eagle CJ, Spicak J, et al. Celecoxib for prevention of colorectal adenomas. N Engl J Med. 2006;355:885–95.PubMedCrossRef
7.
Lev-Ari S, Strier L, Kazanov D, et al. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin Cancer Res. 2005;11:6738–44.PubMedCrossRef
8.
Anand P, Kunnumakkara AB, Newman RA, Aggarwai BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4:807–18.PubMedCrossRef
9.
Prasad S and Aggarwal BB. Herbal medicine: biomolecular and clinical aspects, 2nd edn. CRC press 2011.
10.
Rao CV, Kawamori T, Hamid R, Reddy BS. Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor. Carcinogenesis. 1999;20:641–4.PubMedCrossRef
11.
Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003;23:363–98.PubMed
12.
Rao CV, Rivenson A, Simi B, Reddy BS. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res. 1995;55:259–66.PubMed
13.
Kawamori T, Lubet R, Steele VE, et al. Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer res 1999; 59:597–601.
14.
Mukhopadhyay A, Banerjee S, Stafford LJ, Xia C, Liu M, Aggarwal BB. Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene. 2002;21:8852–61.PubMedCrossRef
15.
Aggrawal BB, Banerjee S, Bharadwaj U, Sung B, Shishodia SG. Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines. Biochem Pharmacol. 2007;73:1024–32.CrossRef
16.
Moos PJ, Edes K, Mullally JE, Fitzpatrick FA. Curcumin impairs tumor suppressor p53 function in colon cancer. Carcinogenesis. 2004;25:1611–7.PubMedCrossRef
17.
He ZY, Shi CB, Wen H, Li FL, Wang J. Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin. Cancer Invest. 2011;29:208–13.PubMedCrossRef
18.
Van Erk MJ, Teuling E, Staal YC, et al. Time- and dose-dependent effects of curcumin on gene expression in human colon cancer cells. J Carcinog. 2004;12:8.CrossRef
19.
Goel A, Boland CR, Chauhan DP. Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett. 2001;172:111–8.PubMedCrossRef
20.
Menon VP, Sudheer AR. Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol. 2007;595:105–25.PubMedCrossRef
21.
Beevers CS, Zhou H, Huang S. Hitting the golden TORget: curcumin’s effects on mTOR signaling. Anticancer Agents Med Chem. 2013;13:988–94.PubMedCrossRef
22.
Hong RL, Spohn WH, Hung MC. Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu. Clin Cancer Res. 1999;5:1884–91.PubMed
23.
Chen A, Xu J, Johnson AC. Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene. 2006;25:278–87.PubMed
24.
Dhandapani KM, Mahesh VB, Brann DW. Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors. J Neurochem. 2007;102:522–38.PubMedCrossRef
25.
Binion DG, Otterson MF, Rafiee P. Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut. 2008;57:1509–17.PubMedCentralPubMedCrossRef
26.
Kuttan G, Kumar KB, Guruvayoorappan C, Kuttan R. Antitumor, anti-invasion, and anti-metastatic effect of curcumin. Adv Exp Med Biol. 2007;595:173–84.PubMedCrossRef
27.
Lin SS, Lai KC, Hsu SC, et al. Curcumin inhibits the migration and invasion of human A549 lung cancer cells through the inhibition of matrix metalloproteinase-2 and -9 and vascular endothelial growth factor (VEGF). Cancer Lett. 2009;285:127–33.PubMedCrossRef
28.
Ray S, Chattopadhyay N, Mitra A, Siddigi M, Chatterjee A. Curcumin exhibits antimetastatic properties by modulating integrin receptors, collagenase activity, and expression of Nm23 and E-cadherin. J Environ Toxicol Oncol. 2003;22:49–58.
29.
Killian PH, Kronski E, Michalik KM, et al. Curcumin inhibits prostate cancer metastasis in vivo by targeting the inflammatory cytokines CXCL1 and -2. Carcinogenesis. 2012;33:2507–19.PubMedCrossRef
30.
Hong J, Bose M, Ju J, et al. Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase. Carcinogenesis. 2004;25:1671–9.PubMedCrossRef
31.
Plummer SM, Holloway KA, Manson MM, et al. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene. 1999;18:6013–20.PubMedCrossRef
32.
Brouet I, Ohshima H. Curcumin, an anti-tumour promoter and anti-inflammatory agent, inhibits induction of nitric oxide synthase in activated macrophages. Biochem Biophys Res Commun. 1995;206:533–40.PubMedCrossRef
33.
Nanji AA, Jokelainen K, Tipoe GL, Rahemtulla A, Thomas P, Dannenberg AJ. Curcumin prevents alcohol-induced liver disease in rats by inhibiting the expression of NF-kappa B-dependent genes. Am J Physiol Gastrointest Liver Physiol. 2003;284:G321–7.PubMed
34.
Cho JW, Lee KS, Kim CW. Curcumin attenuates the expression of IL-1beta, IL-6, and TNF-alpha as well as cyclin E in TNF-alpha-treated HaCaT cells; NF-kappaB and MAPKs as potential upstream targets. Int J Mol Med. 2007;19:469–74.PubMed
35.
Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001;21:2895–900.PubMed
36.
Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004;10:6847–54.PubMedCrossRef
37.
Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as “Curecumin”: from kitchen to clinic. Biochem Pharmacol. 2008;15:787–809.CrossRef
38.
Garcea G, Jones DJ, Singh R, et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer. 2004;90:1011–5.PubMedCentralPubMedCrossRef
39.
40.
Collett GP, Campbell FC. Curcumin induces c-jun N-terminal kinase-dependent apoptosis in HCT116 human colon cancer cells. Carcinogenesis. 2004;23:2183–9.CrossRef
41.
Moussavi M, Assi K, Gomez-Munoz A, Salh B. Curcumin mediates ceramide generation via the de novo pathway in colon cancer cells. Carcinogenesis. 2006;27:1636–44.PubMedCrossRef
42.
Guo LD, Chen XJ, Hu YH, Yu ZJ, Wang D, Liu JZ. Curcumin inhibits proliferation and induces apoptosis of human colorectal cells by activating the mitochondria apoptotic pathway. Phytother Res. 2013;27:422–30.PubMedCrossRef
43.•
He ZY, Shi CB, Wen H, Li FL, Wang BL, Wang J. Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin. Cancer Invest. 2011;29:208–13. The study is one of the few clinical trials that examined the effect of oral curcumin supplementation on patients with CRC. It showed that use of curcumin can improve their general health and lead to weight gain even without generating a change in caloric intake. PubMedCrossRef
44.
Chauhan DP. Chemotherapeutic potential of curcumin for colorectal cancer. Curr Pharm Des. 2002;8:1695–706.PubMedCrossRef
45.
Johnson SM, Gulhati P, Arrieta I, et al. Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signaling. Anticancer Res. 2009;29:3185–90.PubMedCentralPubMed
46.
Beevers CS, Li F, Liu L, Huang S. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int J Cancer. 2006;119:757–64.PubMedCrossRef
47.
48.
Mirza S, Sharma G, Parshad R, Gupta SD, Pandya P, Ralhan R. Expression of DNA methyltransferases in breast cancer patients and to analyze the effect of natural compounds on DNA methyltransferases and associated proteins. J Breast Cancer. 2013;16:23–32.PubMedCentralPubMedCrossRef
49.•
Link A, Balaguer F, Shen Y, Lozano JJ, Leung HC, Boland CR, et al. Curcumin modulates DNA methylation in colorectal cancer cells. PLoS One. 2013;8:e57709. The study is one of the few clinical trials that examined the effect of oral curcumin supplementation on patients with CRC. It showed that use of curcumin can improve their general health and lead to weight gain even without generating a change in caloric intake. PubMedCentralPubMedCrossRef
50.
Chen L, Li WF, Wang HX, et al. Curcumin cytotoxicity is enhanced by PTEN disruption in colorectal cancer cells. World J Gastroenterol. 2013;19:6814–24.PubMedCentralPubMedCrossRef
51.
Innocenti F, Liu W, Chen P, Desai AA, Das S, Ratain MJ. Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. Pharmacol Genet Genomics. 2005;15:295–301.CrossRef
52.
Gupta RA, DuBois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer. 2001;1:11–21.PubMedCrossRef
53.
Arber N, DuBois RN. Nonsteroidal anti-inflammatory drugs and prevention of colorectal cancer. Curr Gastroenterol Rep. 1999;1:441–8.PubMedCrossRef
54.
Solomon SD, McMurray JJ, Pfeffer M, et al. Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Eng J Med. 2005;352:1071–80.CrossRef
55.
Yasunari T, Bhardwaj A, Potdar P, Aggarwal B. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene. 2004;23:9247–58.
56.•
Aroch I, Kraus S, Naumov I, et al. Chemopreventive effects of Coltect, a novel dietary supplement, alone and in combination with 5-aminosalicylic acid in 1,2-dimethylhydrazine-induced colon cancer in rats. Ther Adv Gastroenterol. 2010;3:281–9. Coltect is a novel dietary supplement containing curcumin, green tea, and selenomethionine. Previous reports have suggested that these agents can prevent colorectal cancer (CRC). The chemopreventive effects demonstrated in the study may be of clinical importance, because this safe dietary supplement–drug combination can be administered as a chemopreventive regimen for treatment of CRC. CrossRef
57.
Giladi N, Kazanov D, Shpitz B, Aroch I, Kraus S, Arber N. Curcumin potentiates the pro-apoptotic effects of sulindac sulfone in colorectal cancer. Expert Opin Investig Drugs. 2010;S1:S117–24.CrossRef
58.
Patel BB, Sengupta R, Qazi S, et al. Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int J Cancer. 2008;122:267–73.PubMedCrossRef
59.
Shakibaei M, Mobasheri A, Lueders C, Busch F, Shayan P, Goel A. Curcumin enhances the effect of chemotherapy against colorectal cancer cells by inhibition of NF-Kb and Src protein kinase signaling pathways. PLoS One. 2013;8:e57128.CrossRef
60.
Kunnumankkara AB, Diagaradjane P, Anand P, et al. Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. Int J Cancer. 2009;125:2187–97.CrossRef
Metadata
Title
Curcumin Alone and in Combination for Prevention of Colorectal Cancer
Authors
Nataly Shemesh
Nadir Arber
Publication date
01-03-2014
Publisher
Springer US
Published in
Current Colorectal Cancer Reports / Issue 1/2014
Print ISSN: 1556-3790
Electronic ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-013-0207-0

Other articles of this Issue 1/2014

Current Colorectal Cancer Reports 1/2014 Go to the issue

Prevention and Early Detection (N Arber, Section Editor)

The Microbiota: A New Player in the Etiology of Colorectal Cancer

Prevention and Early Detection (N Arber, Section Editor)

The Clinical Evaluation of Polyposis Syndromes

Prevention and Early Detection (N Arber, Section Editor)

New Imaging Modalities for Identification of Hidden Polyps

Molecular Epidemiology (L Jiao and CR Daniel-MacDougall, Section Editors)

Type II Diabetes, Metformin Use, and Colorectal Neoplasia: Mechanisms of Action and Implications for Future Research

Prevention and Early Detection (N Arber, Section Editor)

Prognosis and Therapeutic Implications for Emerging Colorectal Cancer Subtypes

Molecular Epidemiology (L Jiao and CR Daniel-MacDougall, Section Editors)

Fecal Biomarkers for Research on Dietary and Lifestyle Risk Factors in Colorectal Cancer Etiology
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits